Doxycycline in Acute Traumatic Brain Injury

• Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damnhour University.
• All Participants agreed to take part in this clinical research and provide informed consent. for unconscious participants, the informed consent was obtained from their legally authorized representative.
• Patients with moderate to severe TBI will be enrolled from Tanta university hospitals.
• Serum samples will be collected for measuring the biomarkers.
• Our design is randomized, controlled study.
• All enrolled patients will be divided into 2 groups, Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days, and group (2) will be 25 patients will receive placebo in addition to the standard treatment.
• All patients will be followed up during ICU period.
• Statsicial tests appropriate to the study design will be conducted to evaluate the significance of the results.
• Measuring outcome: the primary outcome is the change in the serum level of acute brain injury biomarkers.
• Results, conclusions, discussion and recommendations will be given.

Inclusion criteria

• Hospital admission in the first 24 h of injury,
• 18 to 90 years of age and
• Both sexes with moderate to severe traumatic brain injury (GCS score ≤ 12).
• Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI

Exclusion criteria

• Hypersensitivity to tetracyclines
• Pregnant and breast feeding women,
• History of autoimmune disease.
• History of receiving chronic steroid treatment and isotretinoin,
• Pre-existing hepatic (AST, ALT greater than 3 times the upper limit of normal) or renal failure (BUN/ Creatinine 20:1; creatinine > 2 mg/dL),
• Known malignancies